Inspire Medical Investors Urged to Seek Lead Role in Securities Suit Over Inspire V Rollout

Overview

• Faruqi & Faruqi, Glancy Prongay & Murray, and The Schall Law Firm are recruiting shareholders to move for lead-plaintiff status in the filed securities class action.
• The putative class covers purchases of Inspire Medical stock from August 6, 2024 through August 4, 2025.
• The complaint cites the company’s August 4, 2025 disclosure of a prolonged Inspire V rollout due to incomplete center training and onboarding, delayed claims-processing software updates, and excess inventory weighing on adoption.
• Inspire cut its 2025 earnings guidance by more than 80% to $0.40–$0.50 per share from $2.20–$2.30, and the stock fell about 32% to close at $87.91 on August 5, 2025.
• According to The Schall Law Firm, the class has not been certified, so investors are not represented by counsel unless and until certification occurs.